Quantcast

Pharma news

CTI BioPharma waiting $10 million milestone from Teva for FDA approving Trisenox for certain leukemia

CTI BioPharma is expecting $10 million milestone in February, 2018 from Teva, related to a milestone for U.S. Food and

Posted in Approval, news | Tagged , , , | Leave a comment

TxCell gets free loan from Bpifrance to develop CAR-Treg program

TxCell got an interest-free loan from Bpifrance, a French government agency, for the preclinical development of its most advanced CAR-Treg

Posted in Approval, news | Tagged , | Leave a comment

FDA and EMA see Novartis’s Kymriah as an option for patients with relapsed or refractory B-cell ALL and DLBCL

The FDA has set Novartis’s Kymriah suspension injection for  patients who have relapsed or refractory diffuse large B-cell lymphona (DLBCL)

Posted in Approval, news | Tagged , , , , , | Leave a comment

Ipsen, Exelixis promising with their treatment for patients with advanced liver cancer

Ipsen and Exelixis on Tuesday said that their phase 3 study of study of cabozantinib in patients with advanced liver

Posted in Approval, news | Tagged , , , , | Leave a comment

Midatech conducts study on childhood brain cancer drug in USA

Midatech Pharma will conduct a study of an investigational new drug for the treatment of the fatal childhood brain cancer

Posted in Approval, news | Tagged , , , , , | Leave a comment

FDA says Teva’s Trisenox injection for certain acute promyelocytic leukemia can be used in combination with tretinon

Israel’s largest drugmaker, and world’s renown generic drug’s leading producer Teva, through it’s USA outpost Teva Ltd, said that that

Posted in Approval, news | Tagged , , , , | Leave a comment

FDA accepts Sandoz’s submition for adalimumad in reference to Humira

Novartises division Sandoz has asked the FDA to review their Biologic License Application for biosimilar adalimumad, related to Humira, for

Posted in Approval, news | Tagged , , | Leave a comment

FDA broadens Boehringer Ingelheim’s afatinib indication to previously untreated, metastatic NSCLC

Boehringer Ingelheim Pharmaceuticals has gotten an approval from the FDA, for a broadened indication of its afatinib for patients with

Posted in Approval, news | Tagged , , | Leave a comment

TiGenix’s Chron disease treatment get further validation

TiGenix’s result from study of Xx601 treatment for Chron’s disease has also been published in one of the leading scientific

Posted in Approval, news | Tagged , | Leave a comment

Shire can market in EU Adynovi for certain hemophilia A patients

The European Commission (EC) has given Shire’s ADYNOVI a green light as an extended half-life recombinant factor VIII (rFVIII) treatment

Posted in Approval, news | Tagged , | Leave a comment